1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Discovery Research Grants in Bipolar Disorder - Cycle 4 is sponsored by BD² (Breakthrough Discoveries for Thriving with Bipolar Disorder). This program supports innovative and collaborative groups of multidisciplinary scientists to improve the understanding of the biological mechanisms that underlie bipolar disorder, examining genetic, molecular, cellular, circuit, and/or behavioral mechanisms.
Get alerted about grants like this
Save a search for “BD² (Breakthrough Discoveries for Thriving with Bipolar Disorder)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
RFA Opportunities - Breakthrough Discoveries (BD²) BD²: Breakthrough Discoveries for thriving with Bipolar Disorder funds science in search of ways to help every person with bipolar disorder thrive. We seek multidisciplinary teams to collaborate and explore the fundamental mechanisms, heterogeneity, progression, and underlying biology of the disorder to dramatically improve systems of care and accelerate research.
Since launch, BD² has invested $105M+ in research commitments. BD² Data Science Fellowship The BD² Data Science Fellowship supports postdoctoral researchers applying data science expertise to existing BD² datasets.
Fellows will work within BD²-funded teams or institutions to advance projects that generate new insights, develop computational tools, and strengthen the network’s ability to better understand the biology, trajectory, and mechanisms of bipolar disorder. Requests for Applications (RFAs) BD² Data Science Fellowship The BD² Data Science Fellowship supports postdoctoral researchers applying data science expertise to existing BD² datasets.
Fellows will work within BD²-funded teams or institutions to advance projects that generate new insights, develop computational tools, and strengthen the network’s ability to better understand the biology, trajectory, and mechanisms of bipolar disorder.
BD² Integrated Network Learning Health Network (LHN) Consultant BD² seeks applications from qualified organizations to serve as a consultant to the Integrated Network’s Learning Health Network (LHN).
The selected partner will provide strategic guidance and implementation support to help advance the LHN into a coordinated system that leverages real-world data and shared learning to improve care and outcomes for people living with bipolar disorder.
Discovery Research, Cycle 4 The Discovery Research program supports an innovative and collaborative group of researchers working together to improve our understanding of the biological mechanisms that underlie bipolar disorder.
For this funding cycle, we especially encourage applications that address the cellular and molecular mechanisms of mood-state switching; biological mechanisms by which manic or depressive episodes are induced by external risk factors; or using experimental pharmacology to test causality of a molecular or circuit-level mechanism underlying mood-state switching.
BD² Integrated Network Mobile Application Partner BD² seeks applications from qualified organizations or teams to develop and manage a comprehensive mobile application system for data collection, monitoring, and analysis for the Integrated Network. The BD² Integrated Network is part of a multidisciplinary initiative to increase the scientific understanding and, ultimately, to improve care and interventions for bipolar disorder.
BD² Integrated Network Site, Wave 2 The BD² Integrated Network, in partnership with people living with bipolar disorder and their care teams, engages a network of collaborating investigators and clinicians to build an unprecedented data ecosystem for bipolar disorder, implement and inform data-driven improvements in care, and generate novel insights for interventional approaches.
Discovery Research, Cycle 3 The Discovery Research program aims to delineate the etiology and biological mechanisms of bipolar disorder, allowing the development of effective interventions. We fund multidisciplinary teams of scientists and clinicians who generate new hypotheses and drive innovation in the exploration of causal mechanisms of bipolar disorder with an eye toward novel treatments.
Discovery Research, Cycle 2 The Discovery Research program supports an innovative and collaborative group of researchers working together to improve our understanding of the biological mechanisms that underlie bipolar disorder.
We seek multidisciplinary teams of scientists to develop targeted and groundbreaking research applications that will examine the genetic, molecular, cellular, circuit, and/or behavioral mechanisms of bipolar disorder.
BD² Integrated Network Clinical Coordinating Center (CCC) As part of the BD² Integrated Network, the CCC provides expert guidance and logistical support including key diagnostics and clinical assessments, Institutional Review Board activities, a rigorous study monitoring plan, and coordination of clinical care activities.
Based on current listing details, eligibility includes: Teams of three to five scientists at academic institutions or research institutes. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Funding amounts vary based on project scope and sponsor guidance. Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.